CD33 and acute myeloid leukemia: Single cell RNA-sequencing30 demonstrated that malignant CD33-expressing AML blasts from RAS mutant patients maintained MHC Class II gene expression, whereas malignant CD33-expressing blasts from MLL-X AML patient samples had reduced expression in comparison to healthy CD33-expressing BM (Fig. 2D).